RT Journal Article
SR Electronic
T1 A quantitative home-use framework for assessing fertility and identifying novel hormone trends by recording urine hormones
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.11.21257023
DO 10.1101/2021.05.11.21257023
A1 Siddharth Pattnaik
A1 Dipankar Das
A1 Varun Akur Venkatesan
YR 2022
UL http://medrxiv.org/content/early/2022/04/11/2021.05.11.21257023.abstract
AB Fertility testing using urinary hormones has been used to effectively improve the likelihood of pregnancy. To provide fertility scores, the existing home-use systems measure one or two hormones. However, the hormone profiles vary depending on cycle duration, fertility-related disorders, drugs and other treatments. Here, we introduce Inito, a mobile-phone connected reader that is scalable to multiple hormone tests. In this report, we assess the accuracy of the quantitative home-based fertility monitor, the Inito Fertility Monitor (IFM), and suggest using IFM as a device to monitor and analyse female hormone patterns. There were two aspects of the study: i. evaluation of the efficacy of IFM in quantifying urinary Estrone-3-glucuronide (E3G), pregnanediol glucuronide (PdG) and luteinizing hormone (LH), and ii. A retrospective study of patients’ hormone profiles using IFM. We observed that with all three hormones, IFM had an accurate recovery percentage and had a CV of less than 10 percent. Furthermore, in predicting the concentration of urinary hormones, IFM showed a high correlation with ELISA. Using Inito in clinical trials, we report a novel criterion for earlier confirmation of ovulation compared to existing criteria. We also present a novel hormone pattern consistent across most menstrual cycles included in the study. In conclusion, the Inito Fertility Monitor is an effective tool for calculating the urinary concentrations of E3G, PdG and LH and can also be used to provide accurate fertility scores and confirm ovulation. In addition, the sensitivity of IFM facilitates the monitoring of menstrual cycle-related hormone patterns, therefore also making it a great tool for physicians to track the hormones of their patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN15534557Funding StatementThe study has been conducted and funded by Samplytics Technologies Pvt. Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB - Sparsh Hospital BangaloreI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available in the manuscript. Any additional data will be made available upon inquiry.